Evaluation of the cost-effectiveness of insulin glargine versus NPH insulin for the treatment of type 2 diabetes in the UK

Author： McEwan Phil Poole Chris D. Tetlow Tony Holmes Paul Currie Craig J.

Publisher： Informa Healthcare

ISSN： 1473-4877

Source： Current Medical Research and Opinion, Vol.23, Iss.1, 2007-02, pp. : 21-31

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Background: People with type 2 diabetes typically require insulin treatment following failure on hypoglycaemic agents. The purpose of this study was to evaluate the relative cost-effectiveness of insulin glargine versus NPH insulin for the treatment of type 2 diabetes in the UK. Insulin glargine has been shown to reduce the likelihood of hypoglycaemia and improve HbA_1c in type 2 diabetes by comparison with NPH insulin.Methods: The study used a discrete event simulation model designed to forecast the costs and health outcome of a cohort of 1000 subjects over 40 years. The two main scenarios involved a difference in the likelihood of hypoglycaemia or a difference in HbA_1c. Prices were in UK£ 2005 costs. Costs and benefits were discounted at 3.5% per year. Effectiveness data were pooled data from randomised clinical trials.Results: The incremental cost–effectiveness ratio of insulin glargine versus NPH insulin was £10 027 per quality adjusted life year under a differential hypoglycaemia-only scenario. The incremental cost–effectiveness ratio of insulin glargine versus NPH insulin was £13 921 per quality adjusted life year under a differential HbA_1c-only scenario. In wide-ranging sensitivity analysis, the ICER was consistently below £20 000 per quality adjusted life year gained.Conclusion: This study was the first to evaluate the relative cost-effectiveness of insulin glargine versus NPH insulin. Insulin glargine resulted in significant health benefits and represents excellent value for money for the treatment of type 2 diabetes in the UK.